Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.